<DOC>
	<DOCNO>NCT02201342</DOCNO>
	<brief_summary>To determine pharmacokinetic profile safety udenafil adolescent Fontan physiology ass short-term pharmacodynamic effect udenafil pharmacodynamic measure exercise capacity , ventricular performance , vascular function .</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Study Udenafil Adolescents</brief_title>
	<detailed_description>A dose escalation trial determine pharmacokinetics , safety tolerance udenafil male female adolescent subject single ventricle physiology undergone Fontan surgical procedure . Pharmacodynamic data also collect evaluate effect udenafil acute exercise performance , peripheral vascular function index myocardial performance . Five udenafil cohort evaluate additional one drug free cohort</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Males females Fontan physiology 1418 year age . 2 . Willingness return center complete blood draw exercise test describe study protocol . 3 . Patients must agree abstain alcohol , caffeinated beverage , grapefruit juice duration trial . 4 . Informed assent subject inform consent parent/legal guardian appropriate . 1 . Noncardiac medical , psychiatric , and/or social disorder would prevent successful completion plan study test would invalidate result . 2 . Height &lt; 132 cm ( minimum height requirement exercise stress test ) . 3 . Known Fontan baffle obstruction , branch pulmonary artery stenosis , pulmonary vein stenosis result mean gradient &gt; 4 mmHg region proximal distal obstruction . 4 . Single lung physiology . 5 . Severe ventricular dysfunction valvular regurgitation ( systemic atrioventricular semilunar valve ) determine review echocardiogram perform close proximity study enrollment . 6 . Significant renal ( serum creatinine &gt; 2.0 ) , hepatic ( serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ) , gastrointestinal biliary disorder could impair absorption , metabolism excretion orally administer medication , base laboratory assessment time screen visit . 7 . Hospitalization acute decompensated heart failure within 12 month precede study enrollment . 8 . A diagnosis active protein lose enteropathy plastic bronchitis . 9 . Active evaluation list heart transplant . 10 . History use phosphodiesterase type 5 inhibitor within three month study enrollment . 11 . Concurrent illness , opinion investigator , preclude participation . 12 . Current therapy alphablockers nitrate . 13 . Pregnancy time enrollment . 14 . Latex allergy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Fontan</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Exercise capacity</keyword>
	<keyword>Maximal Oxygen Consumption</keyword>
	<keyword>Vascular function</keyword>
	<keyword>EndoPAT</keyword>
	<keyword>Myocardial performance</keyword>
</DOC>